2022
Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation
Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. Journal Of The American College Of Cardiology 2022, 79: 1785-1798. PMID: 35512858, PMCID: PMC9097170, DOI: 10.1016/j.jacc.2022.02.047.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAspirinAtrial AppendageAtrial FibrillationFibrinolytic AgentsFrailtyHumansStrokeTreatment OutcomeWarfarinConceptsLeft atrial appendage occlusionAdverse eventsPivotal trialsWatchman deviceTreatment protocolAntithrombotic strategiesAppendage occlusionLower riskFrailty regressionPercutaneous left atrial appendage occlusionNational Cardiovascular Data RegistryContemporary U.S. practiceDual antiplatelet therapyAtrial appendage occlusionConcomitant aspirinPostprocedure careAdjusted riskAntiplatelet therapyAntithrombotic medicationAntithrombotic therapyAtrial fibrillationAdverse outcomesTrial protocolAntithrombotic agentsMedication strategies
2015
Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®
Ghanbari H, Nallamothu BK, Wang Y, Curtis JP. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®. Journal Of The American Heart Association 2015, 4: e001331. PMID: 25637345, PMCID: PMC4345865, DOI: 10.1161/jaha.114.001331.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAtrial FibrillationCoronary Artery DiseaseDefibrillators, ImplantableDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansIncidenceMaleMedicareMiddle AgedPatient DischargePlatelet Aggregation InhibitorsRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationCoronary artery diseaseMajor adverse cardiovascular eventsNational Cardiovascular Data RegistryAdverse cardiovascular eventsDevice-related complicationsAntithrombotic agentsDefibrillator implantationArtery diseaseAtrial fibrillationAntithrombotic therapyBleeding riskCardiovascular eventsThromboembolic eventsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryImplantable Cardioverter-Defibrillator RegistryHigh bleeding riskCombination of DAHospital dischargeICD implantationPrimary outcomeData registryPatientsFibrillation
2007
Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction
McNamara RL, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamothu BK, Peterson ED, Blaney ME, Frederick P, Krumholz HM. Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal Of Cardiology 2007, 100: 1227-1232. PMID: 17920362, PMCID: PMC2715362, DOI: 10.1016/j.amjcard.2007.05.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArrhythmias, CardiacCaliforniaCohort StudiesEmergency Service, HospitalEmergency TreatmentFemaleFibrinolytic AgentsHospital MortalityHumansMaleMedical RecordsMyocardial InfarctionOutcome Assessment, Health CareRegistriesRetrospective StudiesThrombolytic TherapyTime and Motion StudiesTime FactorsConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionNeedle timeFibrinolytic therapyMyocardial infarctionHospital mortalitySymptom onsetOdds ratioReperfusion strategyAdjunctive medicationsHospital arrivalShorter doorTimely administrationNational registryRepresentative cohortPatientsMortalityInfarctionTherapyIndependent effectsCohortMinutesSmaller centersOnsetImpact of delay